Relationship of Marrow Radiation Dose and Timing of Engraftment for Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Volume: 62, Pages: 82 - 82
Published: May 1, 2021
Abstract
82 null Background: null null Patients ≥ 55 years of age with high-risk acute myeloid leukemia (AML) may benefit from an allogeneic hematopoietic stem cell transplantation (HSCT), which is often the only potentially curative therapy available. However, complete remission (CR) is usually a prerequisite for most centers to perform HSCT, as CR predicts an optimal outcome. Many older patients with relapsed/refractory (R/R) AML do not receive HSCT,...
Paper Details
Title
Relationship of Marrow Radiation Dose and Timing of Engraftment for Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Published Date
May 1, 2021
Volume
62
Pages
82 - 82
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.